In the context of chronic myelogenous leukemia (CML), combined BCR-ABL1 and MNK1/2 inhibition was more effective in suppressing in vivo tumor growth in a xenograft model than was a targeted inhibitor against BCR-ABL1 alone [169]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.